GE HealthCare (NASDAQ: GEHC) is a global medical technology company that spun off from General Electric. This healthcare technology leader provides a wide range of healthcare technologies and services, including medical imaging solutions, patient monitoring systems, and diagnostics. The company operates in a competitive field against other major players like Siemens Healthineers and Philips in the medical technology industry.
GE HealthCare is expanding its mammography collaboration with RadNet (NASDAQ: RDNT)'s subsidiary, DeepHealth. This partnership aims to increase global access to DeepHealth's artificial intelligence (AI) solutions. These innovative tools are designed to improve the accuracy and efficiency of breast cancer screening, a key area in diagnostic imaging advancements. Despite this development, some analysts have adjusted their price targets.
As highlighted by Piper Sandler, one analyst lowered their target for GE HealthCare to $88.00 from $96.00. Similarly, Mizuho Securities reduced its price target to $90.00 when the stock was trading at $72.69, reflecting a cautious investment outlook. From a valuation perspective, GE HealthCare trades with a price-to-earnings (P/E) ratio of 20.29. This key financial metric compares the company's stock price to its earnings per share. The company also has a price-to-sales ratio of 1.74 and an enterprise value-to-sales ratio of 2.02, which measure the stock price against its revenues, providing further financial performance indicators.
The company's financial health shows a debt-to-equity ratio of 0.96, indicating its debt is nearly equal to the value owned by shareholders. Furthermore, its current ratio is 1.18. This suggests GE HealthCare has enough current assets, like cash and inventory, to cover its short-term liabilities, highlighting its liquidity position.
